Diagnostics Research Group | San Antonio, TX

Research site

(Unclaimed)

Location

4410 Medical Drive Suite 360, San Antonio, Texas, United States of America

Site insights

Top conditions

Top treatments

Nintedanib

BLU-5937

Gefapixant

MK-7264

Linaclotide

Tanezumab

ALT-801

BIO-11006

BI 1015550

Polypill

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 65 total trials

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-1)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling

Refractory Chronic Cough

Drug: BLU-5937

Drug: Placebo

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approxi...

Enrolling

Alzheimer Disease

Drug: Donanemab

Drug: Placebo

A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE)

The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-...

Active, not recruiting

COVID-19

Biological: mRNA-1283.222

Biological: mRNA-1273.815

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety an...

Active, not recruiting

Cytomegalovirus Infection

Biological: mRNA-1647

Biological: Placebo

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Chronic Kidney Disease (CKD)

Drug: Retatrutide

Drug: Placebo